Division of Pharmacology and Toxicology, Defence Research and Development Establishment, Gwalior, India.
Int J Environ Res Public Health. 2010 Jul;7(7):2745-88. doi: 10.3390/ijerph7072745. Epub 2010 Jun 28.
Chelation therapy is the preferred medical treatment for reducing the toxic effects of metals. Chelating agents are capable of binding to toxic metal ions to form complex structures which are easily excreted from the body removing them from intracellular or extracellular spaces. 2,3-Dimercaprol has long been the mainstay of chelation therapy for lead or arsenic poisoning, however its serious side effects have led researchers to develop less toxic analogues. Hydrophilic chelators like meso-2,3-dimercaptosuccinic acid effectively promote renal metal excretion, but their ability to access intracellular metals is weak. Newer strategies to address these drawbacks like combination therapy (use of structurally different chelating agents) or co-administration of antioxidants have been reported recently. In this review we provide an update of the existing chelating agents and the various strategies available for the treatment of heavy metals and metalloid intoxications.
螯合疗法是降低金属毒性的首选医学治疗方法。螯合剂能够与有毒金属离子结合,形成易于从体内排出的复杂结构,从而将其从细胞内或细胞外空间中去除。2,3-二巯基丙醇长期以来一直是治疗铅或砷中毒的螯合疗法的主要方法,但其严重的副作用促使研究人员开发出毒性较小的类似物。亲水性螯合剂,如间-2,3-二巯基丁二酸,可有效促进肾脏金属排泄,但它们进入细胞内金属的能力较弱。最近有报道称,采用联合治疗(使用结构不同的螯合剂)或联合使用抗氧化剂等新策略来解决这些缺点。在这篇综述中,我们提供了现有螯合剂的最新信息,以及用于治疗重金属和类金属中毒的各种策略。